These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8040109)

  • 21. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
    O'Hare MD; Felmingham D; Grüneberg RN
    Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of carbon dioxide and sub-lethal levels of antibiotics on adherence of coagulase-negative staphylococci to polystyrene and silicone rubber.
    Wilcox MH; Finch RG; Smith DG; Williams P; Denyer SP
    J Antimicrob Chemother; 1991 May; 27(5):577-87. PubMed ID: 1909311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inefficacy of vancomycin and teicoplanin in eradicating and killing Staphylococcus epidermidis biofilms in vitro.
    Claessens J; Roriz M; Merckx R; Baatsen P; Van Mellaert L; Van Eldere J
    Int J Antimicrob Agents; 2015 Apr; 45(4):368-75. PubMed ID: 25614358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. vanA-targeted oligonucleotide DNA probe designed to monitor vancomycin- and teicoplanin-resistant bacteria in surface waters.
    Nakipoglu M; Yilmaz F; Icgen B
    Environ Monit Assess; 2016 Oct; 188(10):569. PubMed ID: 27640164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetics of glycopeptide antibiotics, and the influence of teicoplanin on granulocyte function.
    Lode H; Boeckh M; Höffken G; Kühn M; Gaffal H; Borner K; Koeppe P
    Scand J Infect Dis Suppl; 1990; 72():9-13. PubMed ID: 2151068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital.
    Nakipoglu Y; Derbentli S; Cagatay AA; Katranci H
    BMC Infect Dis; 2005 May; 5():31. PubMed ID: 15871748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro effects of teicoplanin, teicoplanin derivative MDL 62211 and vancomycin on human polymorphonuclear cell function.
    Capodicasa E; Scaringi L; Rosati E; De Bellis F; Sbaraglia G; Marconi P; Del Favero A
    J Antimicrob Chemother; 1991 May; 27(5):619-26. PubMed ID: 1832144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycopeptide susceptibility profiles of nosocomial multiresistant Staphylococcus haemolyticus isolates.
    Tabe Y; Nakamura A; Igari J
    J Infect Chemother; 2001 Sep; 7(3):142-7. PubMed ID: 11810575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of vancomycin and teicoplanin against anaerobic bacteria.
    Robbins MJ; Marais R; Felmingham D; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1987; 13(9):551-4. PubMed ID: 2962846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two conformers of the glycopeptide antibiotic teicoplanin with distinct ligand binding sites.
    Westwell MS; Gerhard U; Williams DH
    J Antibiot (Tokyo); 1995 Nov; 48(11):1292-8. PubMed ID: 8557571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of teicoplanin and vancomycin on Staphylococcus aureus ultrastructure.
    Filice G; Lanzarini P; Orsolini P; Soldini L; Perversi L; Carnevale G; Comolli G; Castelli F
    Microbiologica; 1990 Jul; 13(3):231-7. PubMed ID: 1703262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility of Staphylococci and Enterococci to vancomycin and teicoplanin.
    Guzek A; Korzeniewski K; Nitsch-Osuch A; Rybicki Z; Prokop E
    Adv Exp Med Biol; 2013; 788():125-32. PubMed ID: 23835969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C; Flammini S; Leonildi A; Ciullo I; Tagliaferri E; Menichetti F
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antistaphylococcal activity of teicoplanin in Riyadh, Saudi Arabia.
    Shibl AM; Ishag AH; Durgham SM
    APMIS Suppl; 1988; 3():68-70. PubMed ID: 2972301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin.
    Watanakunakorn C
    J Antimicrob Chemother; 1988 Sep; 22(3):321-4. PubMed ID: 2972670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters.
    Simon VC; Simon M
    Scand J Infect Dis Suppl; 1990; 72():14-9. PubMed ID: 2151061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model.
    Contrepois A; Joly V; Abel L; Pangon B; Vallois JM; Carbon C
    J Antimicrob Chemother; 1988 May; 21(5):621-31. PubMed ID: 2968969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of teicoplanin and vancomycin against gram-positive bacteria from human clinical and veterinary sources.
    Jensen KT; Schønheyder H; Pers C; Thomsen VF
    APMIS; 1992 Jun; 100(6):543-52. PubMed ID: 1535201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of inoculum, medium and serum on the in-vitro susceptibility of coagulase-negative staphylococci to teicoplanin and vancomycin.
    Kennedy HF; Seal DV
    J Antimicrob Chemother; 1996 Jun; 37(6):1103-9. PubMed ID: 8836813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.